Document:

Second Omnibus Amendment February 13, 2006

 Exhibit 10.6 
  
 SECOND OMNIBUS AMENDMENT AND WAIVER 
  
 This Second Omnibus Amendment and Waiver (this “Amendment”), dated as of February 13, 2006, by and between
Accentia Biopharmaceuticals, Inc., a Florida corporation (the “Parent”), The Analytica Group, Inc., a Florida corporation (“Analytica” and, together with the Parent, the “Companies” and, each a
“Company”) and Laurus Master Fund, Ltd., a Cayman Islands company (the “Purchaser”), amends that certain (i) Securities Purchase Agreement, dated as of April 29, 2005 (the “Initial Closing
Date”), by and between the Parent and the Purchaser (as amended, modified or supplemented, the “Securities Purchase Agreement”); (ii) that certain Registration Rights Agreement, dated as of April 29, 2005, by and
between the Parent and the Purchaser (as amended, modified or supplemented, the “Registration Rights Agreement”); (iii) that certain Amended and Restated Secured Convertible Term Note, dated as of April 29, 2005 and
amended and restated as of August 16, 2005, by the Parent in favor of Purchaser in the initial face amount of $5,000,000, and increased to $10,000,000 (as amended, modified or supplemented, the “Term Note”); (iv) that
certain Amended and Restated Secured Convertible Minimum Borrowing Note, dated as of April 29, 2005 and amended and restated as of August 16, 2005, by the Parent and Analytica in favor of Purchaser in the initial face amount of $2,500,000
(as amended, modified or supplemented, the “Minimum Borrowing Note”); (v) that certain Amended and Restated Secured Non-Convertible Revolving Note, dated as of April 29, 2005 and amended and restated as of August 16,
2005, by the Parent and Analytica in favor of Purchaser in the initial face amount of $5,000,000 (as amended, modified or supplemented, the “Revolving Note”); and (v) that certain Security Agreement, dated as of April 29,
2005 between the Parent, Analytica and the Purchaser (as amended, modified or supplemented, the “Security Agreement”, collectively, with the Securities Purchase Agreement, the Registration Rights Agreement, the Term Note, the
Minimum Borrowing Note and the Revolving Note, the “Funding Documents”). Capitalized terms used but not defined herein shall have the meanings given them in the Securities Purchase Agreement and/or the Security Agreement, as
applicable. 
  
 WHEREAS, Laurus has agreed to waive on the terms
and conditions set forth herein, the Events of Default that may have occurred and are continuing as a result of investments made by the Parent in Biovest International, Inc. (“Biovest”) in amounts otherwise prohibited under the
Securities Purchase Agreement and Security Agreement and incurrence by the Parent of Indebtedness from the Missouri State Bank (“MSB”), and, in consideration therefore and in consideration of the other agreements set forth herein,
the receipt and sufficiency of which is hereby acknowledged, the Company has agreed to issue the Additional Warrant (as defined below) to Laurus; and 
  
 WHEREAS, the Company and Laurus have agreed to make certain changes to the Securities Purchase Agreement, the Registration Rights Agreement, the Term
Note, the Minimum Borrowing Note, the Revolving Note and the Security Agreement as set forth herein. 

 NOW, THEREFORE, in consideration of the above, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 
  
 WAIVERS 
  
 1. Effective
as of the Amendment Effective Date (as defined below), Laurus hereby waives each Event of Default that may have arisen under the Funding Documents solely as a result of (x) investments made by the Parent in Biovest in an aggregate amount not to
exceed $[23,750,000], and (y) the incurrence by the Parent and TEAMM Pharmaceuticals, Inc. (“TEAMM”) of Indebtedness from MSB in the aggregate amount not to exceed at any time $3,000,000; 
  
 2. Laurus and each Company hereby agree that the Companies shall not be
required to pay the principal portion of any Monthly Amount (as defined in the Term Note) due on the first business day of January 2006, February 2006, March 2006, April 2006, May 2006 and June 2006 on such dates (collectively,
the “Postponed Principal”); provided that, the Postponed Principal shall be paid in full on the Maturity Date (as defined in the Term Note), together with all other amounts due and payable on such date under the
Securities Purchase Agreement and the Related Agreements. 
  
 AMENDMENTS 
  
 3. Effective as of the Amendment
Effective Date, Section 6.12(e)(w)(z)(I)(B) of the Securities Purchase Agreement is hereby amended by deleting in full said clause (e)(w)(z)(I)(B) of Section 6.12(e) and inserting the following new clause (e)(w)(z)(I)(B) in lieu thereof:

  
 “the aggregate amount of all such investments shall not
exceed at any time outstanding the greater of (1) $[23,750,000] and (2) the maximum amount of investments contractually required pursuant to the Investment Agreement dated as of April 9, 2003 between the Parent and Biovest as in
effect on the date hereof (subject to the anti-dilution related rights granted to the Parent permitting it to invest a discounted amount to offset the dilutive effect of future equity issuances by Biovest as set forth in the Agreement, dated as of
June 16, 2003, between the Parent and Biovest as in effect on the date hereof)” 
  
 4. Effective as of the Amendment Effective Date, the Registration Rights Agreement is hereby amended and restated in the form attached hereto as Exhibit A (the “Amended and Restated Registration Rights
Agreement”); 
  
 5. Effective as of the Amendment
Effective Date, the Term Note is hereby amended and restated in the form attached hereto as Exhibit B (the “Amended and Restated Term Note”). For the avoidance of doubt, the amendment and restatement of the Term Note as set
forth in this Section 5 shall be in substitution for and not in satisfaction of the Term Note; 
  
 6. Effective as of the Amendment Effective Date, the Minimum Borrowing Note is hereby amended and restated in the form attached hereto as Exhibit C
(the “Amended and Restated Minimum Borrowing Note”). For the avoidance of doubt, the amendment and restatement of the Term Note as set forth in this Section 6 shall be in substitution for and not in satisfaction of the Term
Note; 
  
 7. Effective as of the Amendment Effective Date,
the Revolving Note is hereby amended and restated in the form attached hereto as Exhibit D (the “Amended and Restated 

  

 2 

 
Revolving Note”). For the avoidance of doubt, the amendment and restatement of the Term Note as set forth in this Section 7 shall be in
substitution for and not in satisfaction of the Term Note; 
  
 8.
Effective as of the Amendment Effective Date, the Security Agreement is hereby amended and restated in the form attached hereto as Exhibit E (the “Amended and Restated Security Agreement”). 
  
 MISCELLANEOUS 
  
 9. The Parent agrees that is shall issue a Common Stock purchase warrant
(the “Additional Warrant”) to Laurus to purchase up to 62,000 shares of the Common Stock of the Parent with an exercise price of $0.01 per share, such Additional Warrant to be in the form attached hereto as Exhibit F. The
Parent further agrees to file a Registration Statement (as defined in the Registration Rights Agreement), to register the shares of Common Stock that may be issued upon exercise of the Additional Warrant within 30 days of the date hereof (the
“Filing Date”). The Filing Date shall be deemed to be a Filing Date under, and as defined in, the Amended and Restated Registration Rights Agreement. 
  

10. Each amendment and waiver set forth herein shall be effective as of the date first above written (the “Amendment Effective Date”)
on the date when (i) the Parent shall have executed and delivered to Laurus each of the Additional Warrant, the Amended and Restated Registration Rights Agreement and the Amended and Restated Term Note, (ii) each Company shall have
executed and delivered to Laurus the Amended and Restated Minimum Borrowing Note, the Amended and Restated Revolving Note and the Amended and Restated Security Agreement, (iii) Laurus shall have received a duly executed Subordination Agreement
from the MSB in the form attached hereto as Exhibit G, (iv) Laurus shall have received from the Parent and TEAMM a duly executed Joinder Agreement in the form attached hereto as Exhibit H, (v) Laurus shall have received a
Reaffirmation Agreement in the form attached hereto as Exhibit I duly executed by The Francis E. O’Donnell, Jr. Irrevocable Trust No. 1 and (vi) each Company and Laurus shall have executed and each Company shall have delivered
to Laurus its respective counterpart to this Amendment. 
  
 11.
Except as specifically set forth in this Amendment, there are no other amendments, modifications or waivers to the Funding Documents, and all of the other forms, terms and provisions of the Funding Documents remain in full force and effect.

  
 12. Each Company hereby represents and warrants to Laurus that
(i) no Event of Default exists on the date hereof, after giving effect to this Amendment, (ii) on the date hereof, after giving effect to this Amendment, all representations, warranties and covenants made by the Companies in connection
with the Funding Documents are true, correct and complete and (iii) on the date hereof, after giving effect to this Amendment, all of the Parent’s and its Subsidiaries’ covenant requirements have been met. 
  
 13. From and after the Amendment Effective Date, all references in the
Funding Documents shall be deemed to be references to the Funding Documents as modified hereby. 
  

 3 

 14. The Parent understands that the Parent has an affirmative obligation to make prompt public disclosure
of material agreements and material amendments to such agreements. It is the Parent’s determination that neither this Amendment nor the terms and provisions of this Amendment, (collectively, the “Information”) are material. The Parent
has had an opportunity to consult with counsel concerning this determination. The Parent hereby agrees that Laurus shall not be in violation of any duty to the Parent or its shareholders, nor shall Laurus be deemed to be misappropriating any
information of the Parent, if Laurus sells shares of common stock of the Parent, or otherwise engages in transactions with respect to securities of the Parent, while in possession of the Information. 
  
 15. This Amendment shall be binding upon the parties hereto and their
respective successors and permitted assigns and shall inure to the benefit of and be enforceable by each of the parties hereto and their respective successors and permitted assigns. THIS AMENDMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE
WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK. This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which shall constitute one instrument. 
  

 4 

 IN WITNESS WHEREOF, each Company and Laurus has caused this Amendment to the Funding Documents to
be signed in its name effective as of this 13th day of February 2006. 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	 By:
	 	  

	 Name:
	 	 
	 Title:
	 	 
	
	THE ANALYTICA GROUP, INC.
		
	 By:
	 	  

	 Name:
	 	 
	 Title:
	 	 
	
	LAURUS MASTER FUND, LTD.
		
	 By:
	 	  

	 Name:
	 	 
	 Title:
	 	 

  

 5 

 EXHIBIT A 
  

Form of Amended and Restated Registration Rights Agreement 
  

 6 

 EXHIBIT B 
  

Form of Amended and Restated Term Note 
  

 7 

 EXHIBIT C 
  

Form of Amended and Restated Minimum Borrowing Note 
  

 8 

 EXHIBIT D 
  

Form of Amended and Restated Revolving Note 
  

 9 

 EXHIBIT E 
  

Form of Amended and Restated Security Agreement 
  

 10 

 EXHIBIT G 
  

Form of Subordination Agreement 
  

 11 

 EXHIBIT H 
  

Form of Joinder Agreement 
  

 12 

 EXHIBIT I 
  

Form of O’Donnell Trust Reaffirmation Agreement 
  

 13Amended and Restated Secured Note

 Exhibit 10.7 
  
 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS NOTE MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS NOTE UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO ACCENTIA BIOPHARMACEUTICALS,
INC. THAT SUCH REGISTRATION IS NOT REQUIRED. 
  
 AMENDED
AND RESTATED SECURED NON-CONVERTIBLE REVOLVING NOTE 
  
 FOR VALUE RECEIVED, each of ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation (the “Parent”), and the other companies listed on Exhibit A attached hereto (such other companies together with the Parent, each a
“Company” and collectively, the “Companies”), jointly and severally, promises to pay to LAURUS MASTER FUND, LTD., c/o M&C Corporate Services Limited, P.O. Box 309 GT, Ugland House, South Church Street, George
Town, Grand Cayman, Cayman Islands, Fax: 345-949-8080 (the “Holder”) or its registered assigns or successors in interest, the sum of Five Million Dollars ($5,000,000), without duplication of any amounts owing by the Companies to the
Holder under the Second Minimum Borrowing Note (as defined in the Security Agreement referred to below), or, if different, the aggregate principal amount of all Loans (as defined in the Security Agreement referred to below), together with any
accrued and unpaid interest hereon, on April 29, 2006 (the “Maturity Date”) if not sooner indefeasibly paid in full; provided, however, if the Parent shall have consummated the Initial Public Offering (as defined
in the Security Agreement referred to below) on or prior to March 31, 2006, the Maturity Date shall be April 29, 2008. This Secured Non-Convertible Revolving Note amends and restates in its entirety (and is given in substitution for and
not in satisfaction of) that certain $5,000,000 Secured Revolving Note made by the Company in favor of Holder on April 29, 2006. 
  
 Capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Security Agreement among the Companies and the
Holder dated as of the date hereof (as amended and restated, further amended, modified and/or supplemented from time to time, the “Security Agreement”). 
  
 The following terms shall apply to this Amended and Restated Secured Non-Convertible Revolving Note (this
“Note”): 
  
 ARTICLE I 
 CONTRACT RATE AND MINIMUM BORROWING NOTE 
  
 1.1 Contract Rate. Subject to Sections 3.2 and 4.10, interest payable on the outstanding principal amount of this Note (the “Principal
Amount”) shall accrue at a rate per annum equal to the “prime rate” published in The Wall Street Journal from time to time (the “Prime Rate”), plus two percent (2.0%) (the “Contract
Rate”). The Contract Rate shall be increased or decreased as the case may be for each increase or decrease in the Prime Rate in an amount equal to such increase or decrease in the Prime Rate; each change to be effective as of the day of the
change in the Prime Rate. Subject to Section 1.2, the Contract Rate shall not at 

 
any time be less than seven and three-quarters percent (7.75%). Interest shall be (i) calculated on the basis of a 360 day year, and (ii) payable
monthly, in arrears, commencing on May 4, 2005 on the first business day of each consecutive calendar month thereafter through and including the Maturity Date, and on the Maturity Date, whether by acceleration or otherwise. 
  
 1.2 Contract Rate Adjustments and Payments. The Contract Rate shall be
calculated on the last business day of each calendar month hereafter (other than for increases or decreases in the Prime Rate which shall be calculated and become effective in accordance with the terms of Section 1.1) until the Maturity Date
(each a “Determination Date”) and shall be subject to adjustment as set forth herein. 
  
 ARTICLE II 
 [INTENTIONALLY OMITTED] 
  
 ARTICLE III 
 EVENTS OF DEFAULT AND DEFAULT RELATED PROVISIONS 
  
 3.1 Events of Default. The occurrence of an Event of Default under the Security Agreement shall constitute an event of default (“Event of
Default”) hereunder. 
  
 3.2 Default Interest.
Following the occurrence and during the continuance of an Event of Default, the Companies shall, jointly and severally, pay additional interest on the outstanding principal balance of this Note in an amount equal to one and one half percent
(1.5%) per month, and all outstanding Obligations, including unpaid interest, shall continue to accrue interest at such additional interest rate from the date of such Event of Default until the date such Event of Default is cured or waived.

  
 3.3 Default Payment. Following the occurrence and
during the continuance of an Event of Default, the Holder, at its option, may elect, in addition to all rights and remedies of the Holder under the Security Agreement and the other Ancillary Agreements and all obligations and liabilities of each
Company under the Security Agreement and the other Ancillary Agreements, to require the Companies, jointly and severally, to make a Default Payment (“Default Payment”). The Default Payment shall be 130% of the outstanding principal
amount of the Note, plus accrued but unpaid interest, all other fees then remaining unpaid, and all other amounts payable hereunder. The Default Payment shall be applied first to any fees due and payable to the Holder pursuant to the Notes, the
Security Agreement and/or the Ancillary Agreements, then to accrued and unpaid interest due on the Notes and then to the outstanding principal balance of the Notes. The Default Payment shall be due and payable immediately on the date that the Holder
has exercised its rights pursuant to this Section 3.3. 
  
 ARTICLE IV 
 MISCELLANEOUS 
  
 4.1 [Intentionally Omitted]. 
  

 2 

 4.2 Cumulative Remedies. The remedies under this Note shall be cumulative. 
  
 4.3 Failure or Indulgence Not Waiver. No failure or delay on the part
of the Holder hereof in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any
other right, power or privilege. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available. 
  

4.4 Notices. Any notice herein required or permitted to be given shall be in writing and shall be deemed effective given (a) upon personal
delivery to the party notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five days after having been sent by registered or certified
mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the respective
Company at the address provided for such Company in the Security Agreement executed in connection herewith, and to the Holder at the address provided in the Security Agreement for the Holder, with a copy to John E. Tucker, Esq., 825 Third Avenue,
14th Floor, New York, New York 10022, facsimile number (212) 541-4434, or at such other address as the
respective Company or the Holder may designate by ten days advance written notice to the other parties hereto. A Notice of Conversion shall be deemed given when made to the Parent pursuant to the Purchase Agreement. 
  
 4.5 Amendment Provision. The term “Note” and all references
thereto, as used throughout this instrument, shall mean this instrument as originally executed, or if later amended or supplemented, then as so amended or supplemented, and any successor instrument as such successor instrument may be amended or
supplemented. 
  
 4.6 Assignability. This Note shall be
binding upon each Company and its successors and assigns, and shall inure to the benefit of the Holder and its successors and assigns, and may be assigned by the Holder in accordance with the requirements of the Security Agreement. No Company may
not assign any of its obligations under this Note without the prior written consent of the Holder, any such purported assignment without such consent being null and void. 
  
 4.7 Cost of Collection. In case of any Event of Default under this Note, the Companies shall, jointly and severally,
pay the Holder the Holder’s reasonable costs of collection, including reasonable attorneys’ fees. 
  
 4.8 Governing Law, Jurisdiction and Waiver of Jury Trial. 
  

(a) THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF
CONFLICTS OF LAW. 
  
 (b) EACH COMPANY HEREBY CONSENTS AND AGREES
THAT THE STATE OR FEDERAL COURTS LOCATED IN THE COUNTY OF NEW 

  

 3 

 
YORK, STATE OF NEW YORK SHALL HAVE EXCLUSIVE JURISDICTION TO HEAR AND DETERMINE ANY CLAIMS OR DISPUTES BETWEEN ANY COMPANY, ON THE ONE HAND, AND THE HOLDER,
ON THE OTHER HAND, PERTAINING TO THIS NOTE, THE SECURITY AGREEMENT OR ANY OF THE OTHER ANCILLARY AGREEMENTS OR TO ANY MATTER ARISING OUT OF OR RELATED TO THIS NOTE, THE SECURITY AGREEMENT OR ANY OF THE OTHER ANCILLARY AGREEMENTS PROVIDED,
THAT EACH COMPANY ACKNOWLEDGES THAT ANY APPEALS FROM THOSE COURTS MAY HAVE TO BE HEARD BY A COURT LOCATED OUTSIDE OF THE COUNTY OF NEW YORK, STATE OF NEW YORK; AND FURTHER PROVIDED, THAT NOTHING IN THIS NOTE SHALL BE DEEMED OR OPERATE TO
PRECLUDE THE HOLDER FROM BRINGING SUIT OR TAKING OTHER LEGAL ACTION IN ANY OTHER JURISDICTION TO COLLECT THE OBLIGATIONS, TO REALIZE ON THE COLLATERAL OR ANY OTHER SECURITY FOR THE OBLIGATIONS, OR TO ENFORCE A JUDGMENT OR OTHER COURT ORDER IN FAVOR
OF THE HOLDER. EACH COMPANY EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND EACH COMPANY HEREBY WAIVES ANY OBJECTION WHICH IT MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION,
IMPROPER VENUE OR FORUM NON CONVENIENS. EACH COMPANY HEREBY WAIVES PERSONAL SERVICE OF THE SUMMONS, COMPLAINT AND OTHER PROCESS ISSUED IN ANY SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINT AND OTHER PROCESS MAY BE MADE
BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO THE COMPANY AT THE ADDRESS SET FORTH IN THE SECURITY AGREEMENT AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER OF THE COMPANY’S ACTUAL RECEIPT THEREOF OR THREE (3) DAYS AFTER
DEPOSIT IN THE U.S. MAILS, PROPER POSTAGE PREPAID 
  
 (c) EACH
COMPANY DESIRES THAT ITS DISPUTES BE RESOLVED BY A JUDGE APPLYING SUCH APPLICABLE LAWS. THEREFORE, TO ACHIEVE THE BEST COMBINATION OF THE BENEFITS OF THE JUDICIAL SYSTEM AND OF ARBITRATION, EACH COMPANY HERETO WAIVES ALL RIGHTS TO TRIAL BY JURY IN
ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE, WHETHER ARISING IN CONTRACT, TORT, OR OTHERWISE BETWEEN THE HOLDER, AND/OR ANY COMPANY ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM
IN CONNECTION WITH THIS NOTE, THE SECURITY AGREEMENT, ANY OTHER ANCILLARY AGREEMENT OR THE TRANSACTIONS RELATED HERETO OR THERETO. 
  
 4.9 Severability. In the event that any provision of this Note is invalid or unenforceable under any applicable statute or rule of law, then such
provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision of this Note. 
  

 4 

 4.10 Maximum Payments. Nothing contained herein shall be deemed to establish or require the
payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum rate permitted by such law, any payments in
excess of such maximum rate shall be credited against amounts owed by the Companies to the Holder and thus refunded to the Companies. 
  
 4.11 Security Interest and Guarantee. The Holder has been granted a security interest in (i) certain assets of the Companies as more fully
described in the Security Agreement and the Master Security Agreement (ii) the equity interests of certain Subsidiaries of the Parent pursuant to the Stock Pledge Agreement dated as of the date hereof and (iii) the equity interests of Star
Scientific, Inc. held by The Francis E. O’Donnell, Jr. Irrevocable Trust No. 1 pursuant to the O’Donnell Stock Pledge Agreement dated as of the date hereof. The obligations of the Companies under this Note are guaranteed by certain
Subsidiaries of the Parent, pursuant to the Subsidiaries Guaranty dated as of the date hereof. 
  
 4.12 Registered Obligation. This Note is intended to be a registered obligation within the meaning of Treasury Regulation Section 1.871-14(c)(1)(i) and the Companies (or their agent) shall register this
Note (and thereafter shall maintain such registration) as to both principal and any stated interest. Notwithstanding any document, instrument or agreement relating to this Note to the contrary, transfer of this Note (or the right to any payments of
principal or stated interest thereunder) may only be effected by (i) surrender of this Note and either the reissuance by the Companies of this Note to the new holder or the issuance by the Companies of a new instrument to the new holder, or
(ii) transfer through a book entry system maintained by the Companies (or their agent), within the meaning of Treasury Regulation Section 1871-14(c)(1)(i)(B). 
  
 4.13 Construction. Each party acknowledges that its legal counsel participated in the preparation of this Note and,
therefore, stipulates that the rule of construction that ambiguities are to be resolved against the drafting party shall not be applied in the interpretation of this Note to favor any party against the other. 
  
 [Balance of page intentionally left blank; signature page follows] 

 

 5 

 IN WITNESS WHEREOF, each Company has caused this Amended and Restated Secured Non-Convertible
Revolving Note to be signed in its name effective as of this 29th day of April 2005. 
  

					
	 	 	ACCENTIA BIOPHARMACEUTICALS, INC.
			
	 	 	By:	 	  

	 	 	Name:	 	 
	 	 	Title:	 	 
	WITNESS:	 	 	 	 
			
	  

	 	 	 	 
		
	 	 	THE ANALYTICA GROUP, INC.
			
	 	 	By:	 	  

	 	 	Name:	 	 
	 	 	Title:	 	 
	WITNESS :	 	 	 	 
			
	
	 	 	 	 

  

 6 

 EXHIBIT A 
  

OTHER COMPANIES 
  
 THE ANALYTICA GROUP, INC., a Florida corporation

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]